MorphoSys has signed an agreement with Vivoryon Therapeutics to obtain an exclusive option to license the latter’s small molecule glutaminyl-peptide cyclotransferase-like (QPCTL) inhibitors for developing oncology treatments.
PhoreMost, the UK-based biopharmaceutical company, has entered into a structural biology focussed collaboration with the Centre for Chemical Biology and Therapeutics (CCBT), Bangalore, India.
Boehringer Ingelheim has signed a collaboration and license agreement with South Korean pharma company Yuhan, potentially worth up to $870m (£689m), for the latter’s fusion protein for the treatment of Nonalcoholic Steatohepatitis (NASH) and related liver diseases.
Rafael Pharmaceuticals, a leader in the growing field of cancer metabolism-based therapeutics, has entered into an out-licensing agreement with Ono Pharmaceutical, a pharmaceutical company committed to creating innovative medicines.
US-based AbbVie has signed an agreement to acquire Irish pharmaceutical firm Allergan in a deal valued at around $63bn (£49.4bn).
Gilead Sciences and Carna Biosciences announced that the companies have entered into a research and development collaboration to develop and commercialise small molecule compounds in immuno-oncology and to access Carna’s proprietary lipid kinase drug discovery platform.
Alnylam Pharmaceuticals has announced new advances in its RNAi therapeutics platform, including preclinical results demonstrating oral delivery of GalNAc-conjugated small interfering RNAs (siRNAs) – the molecules that mediate RNAi – directed to a liver target.
Janssen Research & Development, LLC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), today announced a collaboration with the University of California, Berkeley (UC Berkeley) and the University of California, San Francisco (UCSF), with the goal of inspiring data-driven approaches to improve health and develop the next generation of leaders in healthcare data sciences.
Gilead Sciences has entered into a strategic collaboration with Nurix Therapeutics for the development of novel therapies for cancer and other diseases.
Mycovia Pharmaceuticals and Jiangsu Hengrui Medicine announced an exclusive agreement to develop and commercialize Mycovia’s investigational drug, VT-1161 (otesaconazole), in China, including mainland China, Hong Kong, Macau, and Taiwan, for the treatment or prevention of a range of fungal conditions, including recurrent vulvovaginal candidiasis (RVVC), onychomycosis and invasive fungal infections.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.